1422975-14-1

Basic information

• Product Name: C₃₇H₅₇NO₇S
• Synonyms: C₃₇H₅₇NO₇S
• CAS NO: 1422975-14-1
• Molecular Weight: 659.928
• Mol File: 1422975-14-1.mol

Chemical Properties

• CAS DataBase Reference: C₃₇H₅₇NO₇S(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₇H₅₇NO₇S(1422975-14-1)
• EPA Substance Registry System: C₃₇H₅₇NO₇S(1422975-14-1)

Safety Data

• Hazardous Substances Data: 1422975-14-1(Hazardous Substances Data)

Upstream product

• 1422975-15-2 C₃₃H₃₉NO₃S 
• 1422974-98-8 C₃₂H₄₄O₇ 
• 81846-19-7 treprostinil 
• 151434-99-0 (1R,2S)-cis-2-benzyloxycarbonyl-cyclohexane-1-carboxylic acid 
• 51224-10-3 1-iodo-6-(trifluoroacetamido)hexane 
• 40248-34-8 6-trifluoroacetamido-1-hexanol 
• 101692-02-8 (1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-1-((S)-3-hydroxyoctyl)-1H-cyclopenta[b]naphthalene-2,5-diol 
• 13149-00-3 1,2-cis-cyclohexanedicarboxylic anhydride 

Relevant articles and documents

Carrier-linked treprostinil prodrugs

The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

PROCESS OF MAKING PROSTACYCLIN COMPOUNDS WITH LINKER THIOL AND PEGYLATED FORMS

A process provides for producing chiral prostacyclin derivatives of Formula (I) in high yield from meso anhydrides.

CARRIER-LINKED TREPROSTINIL PRODRUGS

The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

SUSTAINED RELEASE COMPOSITION OF PROSTACYCLIN

The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.